Fosamax is a prescription medication marketed under the brand name Fosamax. It contains Alendronate Sodium as its active ingredient and belongs to the bone health therapeutic class of drugs known as bisphosphonates. Fosamax is supplied as a pill in two strengths: 35 mg and 70 mg. In Hong Kong, the product is regulated by the Department of Health and requires a prescription from a qualified healthcare professional. The medication is manufactured by Merck & Co., Inc., a globally recognized pharmaceutical company.
Alendronate Sodium belongs to the bisphosphonate family. After oral administration, it is absorbed into the bloodstream and rapidly binds to hydroxyapatite crystals on bone surfaces, especially those undergoing active remodeling. The drug is then taken up by osteoclasts, the cells responsible for breaking down bone tissue. Inside osteoclasts, alendronate interferes with the mevalonate pathway, preventing the formation of essential lipid compounds needed for osteoclast function. As a result:
Because the drug targets cells that are active during the early phase of bone remodeling, its therapeutic effect becomes evident after several weeks of consistent use.
Fosamax is approved in Hong Kong for the following indications:
These approvals are based on clinical trial data demonstrating that weekly alendronate therapy reduces the incidence of vertebral and non-vertebral fractures in the listed populations.
Current peer-reviewed literature provides limited evidence for off-label use of alendronate. Some small studies have explored its role in Paget’s disease of bone, where it is also an approved indication in many jurisdictions, but Hong Kong labeling does not include this use for Fosamax. No robust randomized trials support routine off-label prescribing for other conditions. Therefore, this article does not include off-label applications for Fosamax.
If any of these conditions apply, a healthcare professional should evaluate alternative treatment options.
Practical tip: Always inform your healthcare provider of all prescription drugs, over-the-counter medicines, herbal products, and dietary supplements before starting Fosamax.
Standard dosing:
35 mg tablet taken once weekly for the treatment of post-menopausal or male osteoporosis.
70 mg tablet taken once weekly for glucocorticoid-induced osteoporosis.
Administration instructions:
Take the tablet with a full glass (≈240 mL) of plain water.
Swallow whole; do not crush, chew, or split the tablet.
Take it first thing in the morning, preferably on an empty stomach, at least 30 minutes before any food, drink, or other medication.
Remain upright (sitting or standing) for at least 30 minutes after ingestion; avoid lying down or bending over.
Missed dose:
If you forget a dose, take it as soon as you remember provided it is at least 12 hours before the next scheduled dose.
Do not take a double dose to make up for a missed one.
Overdose:
Symptoms may include severe abdominal pain, vomiting, or diarrhea.
Seek emergency medical attention; treatment is primarily supportive.
Discontinuation:
Fosamax may be stopped under medical supervision. In some cases, a tapering schedule is unnecessary because the drug’s effects persist for several months after cessation.
Abrupt discontinuation without alternative therapy may increase fracture risk; discuss a transition plan with your prescriber.
This article provides educational information about Fosamax and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, but you should discuss the severity of your reflux with a healthcare provider. Fosamax can irritate the esophagus, so taking it with plenty of water on an empty stomach and remaining upright for 30 minutes helps minimize discomfort.
Do not force the tablet down. Contact your prescriber; they may evaluate for esophageal conditions that contraindicate Fosamax or consider an alternative therapy.
Calcium can bind to alendronate and reduce its absorption if taken together. Wait at least 30 minutes after Fosamax before consuming calcium or any multivitamin containing minerals.
Both are oral bisphosphonates that reduce bone resorption. Fosamax (alendronate) is typically taken once weekly, whereas risedronate can be taken daily, weekly, or monthly, depending on the formulation. Efficacy in fracture reduction is comparable, but individual tolerability and dosing convenience may differ.
Yes, but carry the medication in its original labeled container, accompanied by a copy of the prescription and a letter from your physician if possible. Some countries may request proof of medical necessity for controlled substances, though Fosamax is not a controlled drug.
Oral bisphosphonates have been associated with rare cases of osteonecrosis of the jaw, especially after invasive dental work. Inform your dentist that you are on Fosamax so they can plan procedures accordingly and consider a drug holiday if deemed appropriate.
Yes. In Hong Kong, Fosamax is approved for the treatment of osteoporosis in both post-menopausal women and men who have documented low bone mass.
The 35 mg tablets are typically white, round, and debossed with the imprint “ALN 35.” The 70 mg tablets are larger, white, and may have the imprint “ALN 70.” Appearance can vary slightly by manufacturer.
Significant increases in BMD are usually observed after 6-12 months of consistent weekly dosing, although fracture risk reduction can begin earlier. Regular DXA scans help track progress.
While this article does not provide purchasing advice, many health insurers and government schemes cover a portion of the cost for approved osteoporosis medications. Check with your insurer or the Hospital Authority for subsidy information.
